Cardurion’s Novel PDE9 Inhibitor Poised to Transform Heart Failure Care

BURLINGTON, MA – August 27, 2026 – In the relentless battle against chronic heart failure, a condition affecting millions and marked by high mortality rates, the announcement of a potential new class of therapy is a significant event. Cardurion Pharmaceuticals, a clinical-stage biotech firm, has ignited fresh hope across the cardiology community by announcing it will present late-breaking Phase 2 clinical trial results for its novel drug, Tovinontrine. The data, from two large global studies, will be unveiled at the Heart Failure Society of America (HFSA) Annual Scientific Meeting this October.

Tovinontrine is a first-in-class, orally administered phosphodiesterase-9 (PDE9) inhibitor, representing a new therapeutic strategy for a disease where unmet needs remain critically high. The upcoming presentation marks the first time robust Phase 2 data for a PDE9 inhibitor has been completed in heart failure, a milestone that could pave the way for a new standard of care.

“Despite current standard of care, a large unmet medical need remains, and patients with chronic heart failure continue to experience high rates of morbidity and mortality,” said Howard Surks, MD, Chief Medical and Scientific Officer of Cardurion. “It is a major milestone for our company to successfully complete this large, global clinical program in both major types of heart failure, and the results of the CYCLE studies will guide the next stage of clinical development for tovinontrine as we move closer to our goal of bringing this novel PDE9 inhibitor to patients.”

A New Mechanism for a Persistent Challenge

At the heart of Cardurion's innovation is a deep understanding of the body's own protective mechanisms. Healthy hearts respond to stress by releasing natriuretic peptides, hormones that trigger a signaling cascade known as the natriuretic peptide signaling (NPS) pathway. This pathway generates a crucial messenger molecule, cyclic guanosine monophosphate (cGMP), which helps the heart muscle relax, reduces harmful thickening (hypertrophy), and prevents the buildup of scar tissue (fibrosis).

In patients with heart failure, this protective system breaks down. The enzyme phosphodiesterase-9 (PDE9) becomes overactive, aggressively degrading cGMP and silencing its beneficial effects. Cardurion’s Tovinontrine is designed to intervene directly at this point of failure. By selectively inhibiting PDE9, the drug aims to protect the existing cGMP, amplifying the body’s natural cardiac defense system.

Cardiologists and researchers not affiliated with the company note that targeting a clinically validated pathway with a novel mechanism is a promising strategy. “Therapeutic targeting of the NP signaling pathway is precedented by today's standard of care,” one leading academic researcher commented. “PDE9 inhibition represents a new way to activate this pathway to seek improved patient outcomes.” This approach distinguishes Tovinontrine from other heart failure drugs and establishes it as a potentially foundational new therapy.

Confronting the Unmet Need in a Global Epidemic

Heart failure is a staggering public health crisis. In the United States alone, approximately 6.7 million adults live with the condition, and nearly half will die within five years of diagnosis. The disease is a leading cause of hospitalization, placing an immense burden on patients, families, and healthcare systems.

Treatments have advanced significantly, particularly for heart failure with reduced ejection fraction (HFrEF), where the heart’s main pumping chamber is weakened. A formidable arsenal of drugs, including ARNIs, SGLT2 inhibitors, and beta-blockers, has improved survival and quality of life. Yet, even with optimal therapy, morbidity and mortality rates remain stubbornly high.

The challenge is even greater in heart failure with preserved ejection fraction (HFpEF), which accounts for roughly half of all cases. In HFpEF, the heart muscle becomes stiff and cannot relax properly to fill with blood, but therapeutic options have been historically limited and less effective. Cardurion’s clinical program strategically addresses both fronts. The upcoming data comes from two parallel trials: CYCLE-1 REF for patients with HFrEF and CYCLE-2 PEF for those with HFpEF. The results from the CYCLE-2 PEF trial are particularly anticipated, as a positive outcome could offer a breakthrough for a patient population with few proven treatments.

A Biotech's Calculated Bet on Cardiovascular Innovation

Cardurion's journey with Tovinontrine is a case study in strategic, science-driven drug development. The company, which maintains research facilities in both the U.S. and Japan, has methodically built the case for PDE9 inhibition. An earlier Phase 2a study with a precursor compound provided the crucial proof-of-concept, demonstrating that inhibiting PDE9 successfully increased cGMP levels in heart failure patients with a favorable safety profile.

This systematic progress has attracted significant investor confidence. In July 2024, Cardurion closed a massive $260 million Series B financing round, building on a previous $300 million investment from Bain Capital. This war chest is earmarked to advance Tovinontrine into late-stage trials and support the company’s broader pipeline, which includes a novel CaMKII inhibitor for other cardiovascular diseases. This strong financial backing positions Cardurion to independently drive its lead asset through the expensive and complex Phase 3 and regulatory approval process, a rare feat for a clinical-stage biotech.

All Eyes on Phoenix: What to Expect from the CYCLE Data

When Cardurion presents its findings at the HFSA meeting in Phoenix, the medical and investment communities will be scrutinizing the data for several key signals. Beyond the primary endpoint of safety, they will look for clear evidence of efficacy. This includes potential improvements in key biomarkers like NT-proBNP, a measure of cardiac stress, and, importantly, in patient-reported outcomes measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ), which assesses symptoms and quality of life.

The FDA has shown increasing willingness to consider patient-centric endpoints for drug approval, especially in areas of high unmet need like HFpEF. Strong KCCQ data could therefore provide a clear regulatory path forward. The combined results from the HFrEF and HFpEF trials will offer a comprehensive picture of Tovinontrine’s potential role across the full spectrum of chronic heart failure. The results, to be unveiled in October, could not only define the future of Tovinontrine but also signal the arrival of a much-needed new therapeutic class for millions of patients navigating the daily realities of chronic heart failure.